486 related articles for article (PubMed ID: 33920158)
1. Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease.
Millet-Boureima C; He S; Le TBU; Gamberi C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920158
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor as an angiogenesis biomarker for the progression of autosomal dominant polycystic kidney disease.
Martins DP; Souza MA; Baitello ME; Nogueira V; Oliveira CI; Pinhel MA; Caldas HC; Filho MA; Souza DR
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909926
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and autosomal dominant polycystic kidney disease.
Huang JL; Woolf AS; Long DA
Pediatr Nephrol; 2013 Sep; 28(9):1749-55. PubMed ID: 22990303
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of mutations of renal cell carcinoma in an autosomal dominant polycystic kidney disease patient.
Shim KE; Lee C; Kim JU; Choi GH; Kwak KM; Kim SH; Kim H; Yoon JW; Shin TY; Jeong CW; Kim H
Medicine (Baltimore); 2020 May; 99(19):e20071. PubMed ID: 32384474
[TBL] [Abstract][Full Text] [Related]
5. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
[TBL] [Abstract][Full Text] [Related]
6. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma.
Chen F; Bai J; Li W; Mei P; Liu H; Li L; Pan Z; Wu Y; Zheng J
PLoS One; 2013; 8(2):e56241. PubMed ID: 23457532
[TBL] [Abstract][Full Text] [Related]
7. Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma.
Di J; Gao K; Qu D; Yang J; Zheng J
Tumour Biol; 2017 Jul; 39(7):1010428317701653. PubMed ID: 28691643
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in autosomal-dominant polycystic kidney disease.
Bello-Reuss E; Holubec K; Rajaraman S
Kidney Int; 2001 Jul; 60(1):37-45. PubMed ID: 11422734
[TBL] [Abstract][Full Text] [Related]
9. Autosomal dominant polycystic kidney disease: prevalence of renal neoplasias in surgical kidney specimens.
Jilg CA; Drendel V; Bacher J; Pisarski P; Neeff H; Drognitz O; Schwardt M; Gläsker S; Malinoc A; Erlic Z; Nunez M; Weber A; Azurmendi P; Schultze-Seemann W; Werner M; Neumann HP
Nephron Clin Pract; 2013; 123(1-2):13-21. PubMed ID: 23752029
[TBL] [Abstract][Full Text] [Related]
10. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
[TBL] [Abstract][Full Text] [Related]
11. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Hemmerlein B; Galuschka L; Putzer N; Zischkau S; Heuser M
Histopathology; 2004 Dec; 45(6):603-11. PubMed ID: 15569051
[TBL] [Abstract][Full Text] [Related]
13. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
14. Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcinoma.
Klingel R; Dippold W; Störkel S; Meyer zum Büschenfelde KH; Köhler H
Am J Kidney Dis; 1992 Jan; 19(1):22-30. PubMed ID: 1739078
[TBL] [Abstract][Full Text] [Related]
15. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
[TBL] [Abstract][Full Text] [Related]
16. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD).
Norman J
Biochim Biophys Acta; 2011 Oct; 1812(10):1327-36. PubMed ID: 21745567
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Hedgehog signaling suppresses proliferation and microcyst formation of human Autosomal Dominant Polycystic Kidney Disease cells.
Silva LM; Jacobs DT; Allard BA; Fields TA; Sharma M; Wallace DP; Tran PV
Sci Rep; 2018 Mar; 8(1):4985. PubMed ID: 29563577
[TBL] [Abstract][Full Text] [Related]
18. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
20. The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice.
Wang Q; Wang S; Sun SQ; Cheng ZH; Zhang Y; Chen G; Gu M; Yao HJ; Wang Z; Zhou J; Peng YB; Xu MX; Zhang K; Sun XW
Cancer Biomark; 2016; 16(1):1-9. PubMed ID: 26484606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
